Markowitz JE, et al. - Experts assessed the long-term safety and effectiveness of reslizumab (RSZ) in pediatric patients with eosinophilic esophagitis who received RSZ in a randomized controlled trial (RCT) and expanded access program. RSZ 2 mg/kg (or placebo) was administered in patients every 4 weeks as part of the RCT, open-label extension (OLE), and compassionate use (CU). As per data, in children with eosinophilic esophagitis (EoE), RSZ appeared to be safe over 9 years of treatment experience. During treatment with RSZ, considerable improvement in the symptoms (dysphagia, abdominal pain, heartburn, vomiting, reflux) and eosinophil count was seen despite a relatively unrestricted diet.